Cardiol Therapeutics Inc. Files 6-K, Incorporates Exhibit

Ticker: CRDL · Form: 6-K · Filed: Oct 9, 2024 · CIK: 1702123

Sentiment: neutral

Topics: sec-filing, registration-statement, administrative

Related Tickers: CRDL

TL;DR

Cardiol Therapeutics (CRDL) filed a 6-K, incorporating an exhibit into its F-10 registration. No new material info, just an update.

AI Summary

Cardiol Therapeutics Inc. filed a Form 6-K on October 9, 2024, to incorporate Exhibit 99.1 by reference into its existing Registration Statement on Form F-10 (File No. 333-280713). This filing does not contain new financial information but serves to update or supplement the previously filed registration statement.

Why It Matters

This filing indicates an administrative update to an existing registration statement, potentially related to ongoing capital-raising or securities offerings, but doesn't introduce new operational or financial data.

Risk Assessment

Risk Level: low — The filing is administrative and incorporates an existing exhibit into a registration statement, posing no immediate new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to incorporate Exhibit 99.1 by reference into Cardiol Therapeutics Inc.'s Registration Statement on Form F-10 (File No. 333-280713).

What is the filing date of this Form 6-K?

This Form 6-K was filed on October 9, 2024.

Does this filing introduce new financial results for Cardiol Therapeutics Inc.?

No, this filing is administrative and incorporates an existing exhibit; it does not present new financial results.

What is the SEC file number for Cardiol Therapeutics Inc.?

The SEC file number for Cardiol Therapeutics Inc. is 001-40712.

Which registration statement is being supplemented by this filing?

The registration statement being supplemented is on Form F-10, with File No. 333-280713.

Filing Stats: 209 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-10-09 14:17:07

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 9, 2024 By: /s/ Chris Waddick Name: Chris Waddick Title: Chief Financial Officer Form 6-K Exhibit Index Exhibit Number Document Description 99.1 Underwriting Agreement, dated October 9, 2024 99.2 News Release, dated October 9, 2024 – Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing